HERANTIS PHARMA
Desconocido
ReTreatPD: Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
HERANTIS PHARMA OYJ
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2022-ACCELERATOR-01
Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, whereof 1.2 million in the EU....
2023-04-07 - 2025-04-30 | Financiado
2023-04-07 - 2025-04-30 | Financiado
TreatER: Clinical study in Parkinson s disease with two unique goals 1 Proof of concept of CDNF protein for...
HERANTIS PHARMA OYJ
participó en un
H2020:
H2020-SC1-2016-2017
The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of int...
2016-12-09 - 2020-12-31 | Financiado
2016-12-09 - 2020-12-31 | Financiado
* No se disponen de datos de la empresa actual.